Semaglutide and Abatacept to offset revenue losses and 80% of EBITDA impact from the Revlimid patent expiry in 2026.

Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...

B&K Securities is bullish on CarTrade Tech Ltd., and holds that the company is a classic non-linear business with growth ...

Following the demerger of ITC Hotels from ITC Ltd, Nuvama expects an outflow of approximately $180 million due to the ...

Jefferies and other brokerages provide optimistic recommendations on companies like Reliance Industries, Nuvoco Vistas Corp, ...

Despite some growth in rural consumption, India's consumer goods companies grappled with inflation and weak urban demand in ...

Nomura, on January 6, upgraded SBI Card share to ‘Buy’ from ‘Reduce’ on rising share of top metro cities in its new card ...

SBI Card shares rose 5% on January 6 after brokerages Nomura and Nuvama upgraded the stock to 'buy'. Nomura set a target ...

Capital Infra Trust's ₹1,578-crore IPO for infrastructure assets, with anchor investors and road projects, closes on January ...

Passive MF schemes, especially those tracking the Nifty 50 and Sensex, will need to offload their holdings in ITC Hotels as ...

Multi-Manager ICVC also sold 4.35 lakh shares or 0.52 percent stake in Dr Lal PathLabs at Rs 2,997.11 per share.

Media companies are likely to report a subdued performance in the upcoming Q3FY25 results, according to a report by Nuvama.